Mads Liisberg

Mads Liisberg

Auto-generated profile, based on publicly available information

Mads Liisberg

University Hospital Odense

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2023 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
JSJoachim Sejr Skovbo
Joachim Sejr Skovbo
LKLytfi Krasniqi
Lytfi Krasniqi
LOLasse M Obel
Lasse M Obel
EKEgle Kavaliunaite
Egle Kavaliunaite
MLMads Liisberg
Mads Liisberg
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
Large abdominal aortic aneurysms (AAAs) present a significant mortality risk. While numerous medical interventions have been proposed, no drugs have convincingly reduced AAA progression, rupture rates, or repair risk. This systematic review and meta-analysis aimed to assess the impact of repurposed drugs or dietary supplements on slowing expansion rates, reducing the risk of rupture, or minimising the risk of repair for individuals with AAA. A systematic search was conducted in five databases. Both observational studies and randomised controlled trials were included. Unpublished data from two screening trials were incorporated. Risk of bias was assessed using the Newcastle-Ottawa scale and revised Cochrane risk of bias tool. Meta-analyses were performed for each identified drug subclass and were stratified by overall risk of bias. Results were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Of 7 484 screened studies, 39 met the inclusion criteria. No studies on dietary supplements were included. A total of 84 cohorts were derived from the included studies, and twelve distinct drug groups underwent meta-analyses. Two drug groups, metformin and statins, were statistically significant in slowing AAA growth. No low risk of bias studies were included for these two drug groups, and the results had very high heterogeneity (I2 > 80%). Both groups had a GRADE certainty of very low. Metformin, excluding high risk of bias studies, presented an estimated mean growth difference of AAA diameter between users and non-users of -0.73 mm/year, whilst statins had an overall estimated mean difference of -0.84 mm/year. This systematic review and meta-analysis suggests that metformin and statins may provide some effect in slowing AAA progression. However, no definitive evidence was found for any of the investigated drugs included in this study. Further research is needed to identify effective medical treatments for AAA progression with more robust methodology.

14 February 2017 in BMC Medical Imaging
Verified
Journal Article
Open access
PDF file
MLMads Liisberg
Mads Liisberg
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
Validating non-contrast-enhanced computed tomography (nCT) compared to ultrasound sonography (US) as screening method for abdominal aortic aneurysm (AAA) screening. Consecutively attending men (n = 566) from the pilot study of the randomized Danish CardioVascular Screening trial (DANCAVAS trial), underwent nCT and US examination. Diameters were measured in outer-to-outer fashion. Sensitivity and specificity were done testing each modality against each other as reference standard. Measurements were tested for correlation, variance in diameters, and mean differences were tested using paired t-test. Due to logistics, 533 underwent both nCT and US. In four patients, aortae could not be visualized with US, and two of these had an AAA (>30 mm) as diagnosed by nCT. Using nCT 30 (5.7%, 95% CI: 4.2;7.5%) AAA were found. US failed to detect 9 of these, but diagnosed 3 other cases, resulting prevalence by US was 4.5% (95% CI: 3.0;6.6%). Additionally, 5 isolated iliac aneurysms (≥20 mm) (0.9%, 95% CI: 0.3;2.2%) were discovered by nCT. US performed reasonably, with sensitivity ranging from 57.1–70.4%, specificity however, ranged higher 99.2–99.6%. Comparably nCT performed with sensitivity ranging from 82.6–88.9%, nCTs specificity however ranged from 97.7–98.4%. Analysis showed good correlations with no tendency to increasing variance with increasing diameter, and no significant differences between nCT and US with means varying slightly in both axis. nCT seems superior to US concerning sensitivity, and is able to detect aneurysmal lesions not detectable with US. Finally, the prevalence of AAA in Denmark seems to remain relatively high, in this small pilot study group.

1 January 2022 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
LOLasse M Obel
Lasse M Obel
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
ALAnne N Lasota
Anne N Lasota
HJHenrik K Jensen
Henrik K Jensen
LBLeila Louise Benhassen
Leila Louise Benhassen
MLMads Liisberg
Mads Liisberg
Purpose: This study evaluated the validity of the ICD-10 diagnostic codes for aortic dissections (ADs) in the Danish National Patient Registry (DNPR) based upon positive predictive values (PPV). Patients and methods: Cases registered in the DNPR with the unspecific AD diagnostic code DI710 (unspecified AD) from 1996 to 2016, and the specific AD diagnostic codes DI710A (AD Type A) and DI710B (AD Type B) from 2006 to 2016, were included. Available medical records from all registered cases underwent review. Confirmed cases of AD served as “gold standard” when reporting PPV. PPV estimates were stratified by regional differences, date, age at time of diagnosis, and sex. Results: A total of 5018 cases were identified in the DNPR. After merging of data and retrieval of medical records, 3767 cases were eligible for validation. Of these, 2677 cases were verified as AD type A (59.7%), AD type B (38.8%), and unspecified type of AD (1.5%). The average age at diagnosis was 65.1 ± 13.0 years (67.3% males). The overall PPV for having an AD when one of the three diagnostic codes were registered from 1996 to 2016 was 71.1% (95% confidence interval (CI): 69.6– 72.5) and increased significantly over time. From 2006 to 2016, the PPV for the specific AD diagnostic codes was 89.5% (95% CI: 87.4– 91.3), whilst the PPV for the unspecific diagnostic code was 63.5% (95% CI: 61.1– 65.9). Conclusion: We found the overall PPV for the pooled AD diagnostic codes in the DNPR acceptable. However, the two specific AD diagnostic codes presented remarkably higher PPV compared to the unspecific diagnostic code.

8 January 2025 in JACC
Verified
Journal Article
Closed access
LOLasse M Obel
Lasse M Obel
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
JKJoachim S.S. Kristensen
Joachim S.S. Kristensen
Oke GerkeOke Gerke
Oke Gerke
KLKatrine L. Larsen
Katrine L. Larsen
JLJes S. Lindholt
Jes S. Lindholt

20 April 2022 in Annals of Vascular Surgery
Verified
Journal Article
Open access
MLMads Liisberg
Mads Liisberg
FBFrancois Baudier
Francois Baudier
CACengiz Akgül
Cengiz Akgül
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
Thoracic endovascular aortic repair (TEVAR) was introduced in the early 1990s and long-term follow-up studies are warranted in current guidelines. Patients undergoing TEVAR were consecutively included from 1999 to 2019. Thoracic aortic disease includes thoracic aortic aneurysms, aortic dissection, traumatic rupture, penetrating aortic ulcer (PAU), and intramural hematoma (IMH). Our prospective database recorded baseline characteristics, endoleak or aneurysm growth, and death. Patients were included at the time of treatment and censored at death or first reintervention depending on the analysis. Primary end point was all-cause death; secondary end point was reintervention. Survival and failure analyses were done using STATA IC 16.0 and truncated at 15 years of follow-up. Two hundred and fifty six patients were included and 63% were men. Their mean age at intervention was 66.2 ± 14.5 years and they were followed for a mean of 5.2 ± 4.5 years. Indications for TEVAR were acute aortic syndrome in 40.6%, chronic aortic disease in 44.5%, and traumatic rupture in 14.8%. Technical success was seen in 94.1% of the operations, and the left subclavian artery was covered in 27.7%. A 30-day mortality rate was 21.2% (22/104) and 1.75% (2/114) (P < 0.001) for urgent and elective patients, respectively. Twelve patients (4.7%) died within 24 hr of treatment. Overall, long-term mortality recorded 112 (43.8%) deaths, 29 patients had reinterventions (11.3 %, 95% confidence interval: 7.7-15.9), and aneurysms accounted for 62.1% of all reinterventions. Twenty four (82.8%) reinterventions occurred within the first 5 years. This long-term follow-up study shows excess mortality in patients treated for acute aortic syndrome compared to chronic aortic disease, within the first 30 days; this difference diminishes at the end of follow-up. Most endoleaks occur within the first 5 years, although new endoleaks continue to develop decades after in previous endoleak-free patients calling for lifelong surveillance.

17 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
MLMads Liisberg
Mads Liisberg
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
KLKatrine Lawaetz Larsen
Katrine Lawaetz Larsen
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
JHJesper Hallas
Jesper Hallas
LOLasse M Obel
Lasse M Obel
Background: Recommendations for beta blockers in preventing aortic dissection (AD) and improving postdissection survival in nonsyndromic patients with hypertension are based on limited evidence. Methods: This nationwide, population‐based study combined a nested case–control and historical cohort design. Using Danish health care registries, all hospitalized adult patients with AD from 1996 to 2016 were identified and validated. Patients with bicuspid aortic valves or connective tissue disorders were excluded. In the case–control analysis, 1657 validated AD cases were matched 1:10 (±1) with 16 139 controls with hypertension based on age, sex, index date, and cumulative antihypertensive drug use. Long‐term beta blocker use was defined as ≥2000 defined daily doses (DDD). In the cohort analysis, 2120 validated survivors of AD were followed for 5 years to assess postdissection mortality stratified by beta blocker use. Results: Long‐term beta blocker use was associated with increased odds of AD type A (adjusted odds ratio [aOR], 1.7 [95% CI, 1.3–2.3]) and AD type B (aOR, 3.7 [95% CI, 2.7–5.2]) compared with never‐users. A dose‐dependent risk increase was observed for AD type B (aOR, 1.4 [95% CI, 0.8–2.2] for DDD 100–199; aOR, 3.9 [95% CI, 1.6–9.8] for DDD ≥10 000). Beta blocker use was associated with higher 5‐year all‐cause mortality in survivors of AD type A (adjusted hazard ratio [aHR], 1.5 [95% CI, 0.99–2.23]) and AD type B (aHR, 1.5 [95 %CI, 1.0–2.3]) compared with never‐users. Conclusions: Beta blocker use did not reduce AD risk or improve outcomes in survivors of AD compared with other antihypertensive agents. Although clinically relevant data as aortic diameters and blood pressure were not available, these findings challenge current clinical practice and highlight the need for randomized trials.